Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
CLDN18.2 expression
i
Other names:
CLDN18, Claudin-18, Surfactant, Pulmonary Associated Protein J, Surfactant Associated 5, SFTA5, SFTPJ
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
51208
Related biomarkers:
Expression
Fusion
‹
CLDN18 fusion (1)
CLDN18-ARHGAP fusion (1)
CLDN18 fusion (1)
CLDN18-ARHGAP fusion (1)
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
CLDN18.2 expression
Esophageal Adenocarcinoma
CLDN18.2 expression
Esophageal Adenocarcinoma
zolbetuximab
Sensitive: C2 – Inclusion Criteria
zolbetuximab
Sensitive
:
C2
zolbetuximab
Sensitive: C2 – Inclusion Criteria
zolbetuximab
Sensitive
:
C2
CLDN18.2 expression
Gastroesophageal Junction Adenocarcinoma
CLDN18.2 expression
Gastroesophageal Junction Adenocarcinoma
zolbetuximab
Sensitive: C2 – Inclusion Criteria
zolbetuximab
Sensitive
:
C2
zolbetuximab
Sensitive: C2 – Inclusion Criteria
zolbetuximab
Sensitive
:
C2
CLDN18.2 expression
Gastric Adenocarcinoma
CLDN18.2 expression
Gastric Adenocarcinoma
zolbetuximab
Sensitive: C2 – Inclusion Criteria
zolbetuximab
Sensitive
:
C2
zolbetuximab
Sensitive: C2 – Inclusion Criteria
zolbetuximab
Sensitive
:
C2
CLDN18.2 expression
Pancreatic Cancer
CLDN18.2 expression
Pancreatic Cancer
SOT102
Sensitive: C2 – Inclusion Criteria
SOT102
Sensitive
:
C2
SOT102
Sensitive: C2 – Inclusion Criteria
SOT102
Sensitive
:
C2
CLDN18.2 expression
Gastric Cancer
CLDN18.2 expression
Gastric Cancer
SOT102
Sensitive: C2 – Inclusion Criteria
SOT102
Sensitive
:
C2
SOT102
Sensitive: C2 – Inclusion Criteria
SOT102
Sensitive
:
C2
CLDN18.2 expression
Pancreatic Cancer
CLDN18.2 expression
Pancreatic Cancer
ASP2138
Sensitive: C2 – Inclusion Criteria
ASP2138
Sensitive
:
C2
ASP2138
Sensitive: C2 – Inclusion Criteria
ASP2138
Sensitive
:
C2
CLDN18.2 expression
Gastric Cancer
CLDN18.2 expression
Gastric Cancer
ASP2138
Sensitive: C2 – Inclusion Criteria
ASP2138
Sensitive
:
C2
ASP2138
Sensitive: C2 – Inclusion Criteria
ASP2138
Sensitive
:
C2
CLDN18.2 expression
Pancreatic Cancer
CLDN18.2 expression
Pancreatic Cancer
EO-3021
Sensitive: C2 – Inclusion Criteria
EO-3021
Sensitive
:
C2
EO-3021
Sensitive: C2 – Inclusion Criteria
EO-3021
Sensitive
:
C2
CLDN18.2 expression
Gastric Cancer
CLDN18.2 expression
Gastric Cancer
EO-3021
Sensitive: C2 – Inclusion Criteria
EO-3021
Sensitive
:
C2
EO-3021
Sensitive: C2 – Inclusion Criteria
EO-3021
Sensitive
:
C2
CLDN18.2 expression
Solid Tumor
CLDN18.2 expression
Solid Tumor
EO-3021
Sensitive: C2 – Inclusion Criteria
EO-3021
Sensitive
:
C2
EO-3021
Sensitive: C2 – Inclusion Criteria
EO-3021
Sensitive
:
C2
CLDN18.2 expression
Lung Cancer
CLDN18.2 expression
Lung Cancer
EO-3021
Sensitive: C2 – Inclusion Criteria
EO-3021
Sensitive
:
C2
EO-3021
Sensitive: C2 – Inclusion Criteria
EO-3021
Sensitive
:
C2
CLDN18.2 expression
Esophageal Cancer
CLDN18.2 expression
Esophageal Cancer
AZD5863
Sensitive: C2 – Inclusion Criteria
AZD5863
Sensitive
:
C2
AZD5863
Sensitive: C2 – Inclusion Criteria
AZD5863
Sensitive
:
C2
CLDN18.2 expression
Pancreatic Cancer
CLDN18.2 expression
Pancreatic Cancer
AZD5863
Sensitive: C2 – Inclusion Criteria
AZD5863
Sensitive
:
C2
AZD5863
Sensitive: C2 – Inclusion Criteria
AZD5863
Sensitive
:
C2
CLDN18.2 expression
Gastric Cancer
CLDN18.2 expression
Gastric Cancer
AZD5863
Sensitive: C2 – Inclusion Criteria
AZD5863
Sensitive
:
C2
AZD5863
Sensitive: C2 – Inclusion Criteria
AZD5863
Sensitive
:
C2
CLDN18.2 expression
Gastric Cancer
CLDN18.2 expression
Gastric Cancer
Q-1802
Sensitive: C3 – Early Trials
Q-1802
Sensitive
:
C3
Q-1802
Sensitive: C3 – Early Trials
Q-1802
Sensitive
:
C3
CLDN18.2 expression
Gastroesophageal Cancer
CLDN18.2 expression
Gastroesophageal Cancer
TJ-CD4B
Sensitive: C3 – Early Trials
TJ-CD4B
Sensitive
:
C3
TJ-CD4B
Sensitive: C3 – Early Trials
TJ-CD4B
Sensitive
:
C3
CLDN18.2 expression
Pancreatic Cancer
CLDN18.2 expression
Pancreatic Cancer
CT041
Sensitive: C4 – Case Studies
CT041
Sensitive
:
C4
CT041
Sensitive: C4 – Case Studies
CT041
Sensitive
:
C4
CLDN18.2 expression
Pancreatic Cancer
CLDN18.2 expression
Pancreatic Cancer
IBI-345
Sensitive: C4 – Case Studies
IBI-345
Sensitive
:
C4
IBI-345
Sensitive: C4 – Case Studies
IBI-345
Sensitive
:
C4
CLDN18.2 expression
Gastric Cancer
CLDN18.2 expression
Gastric Cancer
IBI-345
Sensitive: C4 – Case Studies
IBI-345
Sensitive
:
C4
IBI-345
Sensitive: C4 – Case Studies
IBI-345
Sensitive
:
C4
CLDN18.2 expression
Gastroesophageal Junction Adenocarcinoma
CLDN18.2 expression
Gastroesophageal Junction Adenocarcinoma
IBI-345
Sensitive: C4 – Case Studies
IBI-345
Sensitive
:
C4
IBI-345
Sensitive: C4 – Case Studies
IBI-345
Sensitive
:
C4
CLDN18.2 expression
Pancreatic Cancer
CLDN18.2 expression
Pancreatic Cancer
ZL-1211
Sensitive: D – Preclinical
ZL-1211
Sensitive
:
D
ZL-1211
Sensitive: D – Preclinical
ZL-1211
Sensitive
:
D
CLDN18.2 expression
Gastric Cancer
CLDN18.2 expression
Gastric Cancer
ZL-1211
Sensitive: D – Preclinical
ZL-1211
Sensitive
:
D
ZL-1211
Sensitive: D – Preclinical
ZL-1211
Sensitive
:
D
CLDN18.2 expression
Solid Tumor
CLDN18.2 expression
Solid Tumor
TJ-CD4B
Sensitive: D – Preclinical
TJ-CD4B
Sensitive
:
D
TJ-CD4B
Sensitive: D – Preclinical
TJ-CD4B
Sensitive
:
D
CLDN18.2 expression
Lung Adenocarcinoma
CLDN18.2 expression
Lung Adenocarcinoma
SOT102
Sensitive: D – Preclinical
SOT102
Sensitive
:
D
SOT102
Sensitive: D – Preclinical
SOT102
Sensitive
:
D
CLDN18.2 expression
Colon Cancer
CLDN18.2 expression
Colon Cancer
SOT102
Sensitive: D – Preclinical
SOT102
Sensitive
:
D
SOT102
Sensitive: D – Preclinical
SOT102
Sensitive
:
D
CLDN18.2 expression
Hepatocellular Cancer
CLDN18.2 expression
Hepatocellular Cancer
SOT102
Sensitive: D – Preclinical
SOT102
Sensitive
:
D
SOT102
Sensitive: D – Preclinical
SOT102
Sensitive
:
D
CLDN18.2 expression
Endometrial Cancer
CLDN18.2 expression
Endometrial Cancer
CLDN18.2-targeted antibody-drug conjugate
Sensitive: D – Preclinical
CLDN18.2-targeted antibody-drug conjugate
Sensitive
:
D
CLDN18.2-targeted antibody-drug conjugate
Sensitive: D – Preclinical
CLDN18.2-targeted antibody-drug conjugate
Sensitive
:
D
CLDN18.2 expression
Ovarian Cancer
CLDN18.2 expression
Ovarian Cancer
CLDN18.2-targeted antibody-drug conjugate
Sensitive: D – Preclinical
CLDN18.2-targeted antibody-drug conjugate
Sensitive
:
D
CLDN18.2-targeted antibody-drug conjugate
Sensitive: D – Preclinical
CLDN18.2-targeted antibody-drug conjugate
Sensitive
:
D
CLDN18.2 expression
Gastric Cancer
CLDN18.2 expression
Gastric Cancer
TJ-CD4B
Sensitive: D – Preclinical
TJ-CD4B
Sensitive
:
D
TJ-CD4B
Sensitive: D – Preclinical
TJ-CD4B
Sensitive
:
D
CLDN18.2 expression
Gastric Cancer
CLDN18.2 expression
Gastric Cancer
nivolumab + TJ-CD4B
Sensitive: D – Preclinical
nivolumab + TJ-CD4B
Sensitive
:
D
nivolumab + TJ-CD4B
Sensitive: D – Preclinical
nivolumab + TJ-CD4B
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login